Double-blind, controlled trial of inositol treatment of depression
- 1 May 1995
- journal article
- clinical trial
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 152 (5) , 792-794
- https://doi.org/10.1176/ajp.152.5.792
Abstract
CSF levels of inositol have been reported to be lower than normal in depressed subjects. The authors administered inositol to depressed patients in a double-blind, controlled trial. Under double-blind conditions, 12 g/day of inositol (N = 13) or placebo (N = 15) was administered to depressed patients for 4 weeks. The overall improvement in scores on the Hamilton Depression Rating Scale was significantly greater for inositol than for placebo at week 4. No changes were noted in hematology or in kidney or liver function. This may be the first use of the precursor strategy for a second messenger rather than a neurotransmitter in treating depression. Although inositol had a significant antidepressant effect in this study, replication is crucial.Keywords
This publication has 7 references indexed in Scilit:
- Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depressionBiological Psychiatry, 1993
- Inositol treatment raises CSF inositol levelsBrain Research, 1993
- Inositol 6 g daily may be effective in depression but not in schizophreniaHuman Psychopharmacology: Clinical and Experimental, 1993
- Second messenger systems and psychoactive drug action: focus on the phosphoinositide system and lithiumAmerican Journal of Psychiatry, 1989
- High-dose dietarymyo-inositol supplementation does not alter the ischaemia phenomenon in human diabeticsActa Neurologica Scandinavica, 1989
- Respiratory distress syndrome and inositol supplementation in preterm infants.Archives of Disease in Childhood, 1986
- RAISED PLASMA-MYOINOSITOL LEVELS IN URÆMIA AND EXPERIMENTAL NEUROPATHYThe Lancet, 1973